PMID- 23533812
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20130328
LR  - 20211021
IS  - 2090-5661 (Print)
IS  - 2090-567X (Electronic)
IS  - 2090-5661 (Linking)
VI  - 2013
DP  - 2013
TI  - Tumor Inhibition by DepoVax-Based Cancer Vaccine Is Accompanied by Reduced 
      Regulatory/Suppressor Cell Proliferation and Tumor Infiltration.
PG  - 753427
LID - 10.1155/2013/753427 [doi]
LID - 753427
AB  - A successful cancer vaccine needs to overcome the effects of immune-suppressor 
      cells such as Treg lymphocytes, suppressive cytokine-secreting Tr1 cells, and 
      myeloid-derived suppressor cells (MDSCs), while enhancing tumor-specific immune 
      responses. Given the relative poor efficacy associated with current cancer 
      vaccines, a novel vaccine platform called DepoVax(TM) (DPX) was developed. C3 
      tumor-challenged mice were immunized with HPV-E7 peptide in DPX- or 
      conventional-emulsion- (CE-) based vaccine. While control mice showed marked 
      increase in Treg/MDSCs in spleen and blood, in mice treated with DPX-E7 the 
      levels remained similar to tumor-free naive mice. Such differences were also seen 
      within the tumor. Antigen-specific IL10-secreting CD4/CD8 T cells and TGF- beta 
      (+)CD8(+) T cell frequencies were increased significantly in CE-treated and 
      control mice in contrast to DPX-E7-immunized mice. Analysis of tumor-infiltrating 
      cells revealed higher frequency of suppressor cells in untreated controls than in 
      DPX-E7 group while the converse was true for tumor-infiltrating CD8 T cells. 
      Immunization of tumor-bearing HLA-A2 transgenic mice with human vaccine DPX-0907, 
      a peptide-based vaccine for breast/ovarian/prostate cancers, showed efficient 
      induction of immune response to cancer peptides despite the presence of 
      suppressor cells. Thus, this study provides the rationale for using DPX-based 
      cancer vaccines in immune-suppressed cancer patients, to induce effective 
      anticancer immunity.
FAU - Karkada, Mohan
AU  - Karkada M
AD  - Immunovaccine Inc., Division of Immunology, 1344 Summer Street, Halifax, NS, 
      Canada B3H 0A8 ; Department of Microbiology and Immunology, Dalhousie University, 
      5850 College Street, Halifax, NS, Canada B3H 4R2.
FAU - Quinton, Tara
AU  - Quinton T
FAU - Blackman, Rachelle
AU  - Blackman R
FAU - Mansour, Marc
AU  - Mansour M
LA  - eng
PT  - Journal Article
DEP - 20130307
PL  - Egypt
TA  - ISRN Oncol
JT  - ISRN oncology
JID - 101567026
PMC - PMC3606802
EDAT- 2013/03/28 06:00
MHDA- 2013/03/28 06:01
PMCR- 2013/03/07
CRDT- 2013/03/28 06:00
PHST- 2013/01/15 00:00 [received]
PHST- 2013/02/06 00:00 [accepted]
PHST- 2013/03/28 06:00 [entrez]
PHST- 2013/03/28 06:00 [pubmed]
PHST- 2013/03/28 06:01 [medline]
PHST- 2013/03/07 00:00 [pmc-release]
AID - 10.1155/2013/753427 [doi]
PST - ppublish
SO  - ISRN Oncol. 2013;2013:753427. doi: 10.1155/2013/753427. Epub 2013 Mar 7.